RVLP - RVL Pharmaceuticals stock rises on preliminary Q1 sales of eye drug Upneeq

RVL Pharmaceuticals (NASDAQ:RVLP) said preliminary Q1 2022 net product sales of eye drug Upneeq is $5.9M. On March 30, the company said it expected Upneeq sales to be in the range of $5.5M to 6M, while reporting its Q4 results. Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1%, is approved in the U.S. for blepharoptosis, or droopy eyelid. "During the first quarter of 2022, we recorded sales to approximately 1,000 new medical aesthetic practices and have already begun seeing meaningful reorders," said RVL CEO Brian Markison. RVLP +5.33% premarket to $1.78

For further details see:

RVL Pharmaceuticals stock rises on preliminary Q1 sales of eye drug Upneeq